Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.79
Bid: 93.35
Ask: 93.36
Change: 0.00 (0.00%)
Spread: 0.01 (0.011%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 90.79
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

STOXX 600 closes at record high on earnings, rate cut optimism

Fri, 10th May 2024 17:21

Rio Tinto considered bid for BHP-target Anglo American -report

*

Green energy production in Italy boosts Enel's Q1 results

*

Medical gear maker Getinge plummets after FDA's safety warning

*

Italy industry output posts unexpected fall in March

May 10 (Reuters) - Europe's main stock index closed at a record high on Friday, on track for its biggest weekly gain since late January, as risk appetite was bolstered by growing bets on interest rate cuts in the region and a strong earnings season.

The pan-European STOXX 600 ended 0.7% higher, with indexes in major economies Germany and France finishing at record highs.

European shares have resumed their record-breaking rally, with the STOXX 600 notching a 3% weekly gain, after investors took a breather in April.

The euphoria around artificial intelligence and monetary policy easing, among others, had sparked bumper gains in the region's stocks since late 2023.

Highlighting Europe's divergence from the U.S. Federal Reserve and boosting equities, the Bank of England hinted at summer rate cuts and Sweden's Riksbank delivered its first cut since 2016 earlier this week.

Minutes from the ECB's April policy meeting showed that policymakers favoured kicking off the monetary policy easing cycle in June, while remaining confident that inflation is on track to fall back to 2% next year.

"Looking beyond June, the path for the bank is anything but clear. The risk of reflation has clearly increased," said Carsten Brzeski, global head of macro at ING Research.

"Any signs of reflation and also stronger economic activity would limit the ECB's room for manoeuvre."

Leading sectoral gains, utilities advanced 1.4%, with Italy's Enel climbing 3.8% following a higher first-quarter core profit. Portugal's largest utility firm EDP climbed 3.9% after a bigger-than-expected jump in first-quarter net profit.

Retailers added 1.5%, with Zalando rising 3.3% after Berenberg upgraded the German online retailer to "buy" from "hold".

Among M&A developments, shares of BBVA and Sabadell were up 1.3% and 0.5%, respectively, as investors assessed the developments around the first hostile banking takeover bid in Spain since the 1980s.

Anglo American advanced 1.4% after a report said mining giant Rio Tinto had considered an offer for the British miner.

Sanofi rose 1.3% after Novavax struck a licensing deal of up to $1.2 billion with French drugmaker for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at double its current market capitalisation.

On the flip side, Getinge slumped 8.8% to the bottom of the STOXX after the U.S. FDA issued a warning on the safety of two of the Swedish medical equipment maker's heart devices.

Symrise shed 1.4% after Berenberg downgraded the German flavour and fragrance maker to "hold" from "buy".

On the data front, Italian industrial output was much weaker than expected in March, extending the pain for the country's struggling manufacturing sector. (Reporting by Ankika Biswas and Johann M Cherian in Bengaluru; Editing by Rashmi Aich, Eileen Soreng and Jane Merriman)

More News
12 Aug 2022 09:01

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi <SASY.PA and Haleon began to stabilise on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Read more
11 Aug 2022 22:15

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Read more
11 Aug 2022 18:45

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Read more
11 Aug 2022 17:29

European shares tick higher; Aegon shines on forecast raise

Aug 11 (Reuters) - European shares edged higher on Thursday after a strong rally in the previous session on signs of U.S. inflation cooling, while Aegon climbed after the Dutch insurer raised its full-year forecast.

Read more
11 Aug 2022 12:23

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.

Read more
10 Aug 2022 17:02

European bourses hold on to U.S. CPI boost

Aug 10 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

EUROPEAN BOURSES HOLD ON TO U.S. CPI BOOST (1150 EDT/1550 GMT)

Read more
9 Aug 2022 16:59

European shares slip with U.S. inflation data in focus

Aug 9 (Reuters) - European shares dipped on Tuesday as investors cautiously waited for key U.S. inflation data later in the week for hints on the Federal Reserve's next move on interest rate increases.

Read more
28 Jul 2022 07:20

Sanofi lifts profit outlook as Dupixent sales surge 43%

July 28 (Reuters) - French healthcare group Sanofi lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.

Read more
19 Jul 2022 13:00

As COVID patent war rages on, pharma group seeks fairer future access

LONDON, July 19 (Reuters) - An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for COVID-19 interventions between the pharmaceutical industry and developing nations endures.

Read more
18 Jul 2022 12:19

GSK's consumer arm Haleon debuts with lacklustre valuation

LONDON, July 18 (Reuters) - British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade, but the unit's market value of 30.5 billion pounds fell well short of the price rival Unilever offered to pay earlier this year.

Read more
7 Jul 2022 15:25

EU drugs regulator open to COVID boosters that target older Omicron offshoots

LONDON, July 7 (Reuters) - The European Medicines Agency (EMA) is open to using next generation COVID-19 vaccines that target older offshoots of the Omicron variant this fall, an official said on Thursday, amid a rise in cases due to new Omicron subvariants.

Read more
24 Jun 2022 17:19

European shares mark strong end to nervous week

June 24 (Reuters) - European stocks jumped 2.6% on Friday, pushing them into positive territory for the week as investors started to scale back central bank tightening bets, spurring inflows into risky assets.

Read more
24 Jun 2022 17:08

Defensive stocks lead rebound in FTSE 100

June 24 (Reuters) - UK's FTSE 100 rose on Friday, lifted by defensive stocks at the end of a choppy week that saw investor anxiety over hawkish central banks, weak economic readings and heightened risks of a global recession.

Read more
24 Jun 2022 09:51

Sanofi, GSK variant-specific COVID shot found effective against Omicron

PARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

Read more
13 Jun 2022 09:09

Sanofi says next-gen COVID booster shot has potential against main variants

PARIS, June 13 (Reuters) - French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.